Beijing Sun-Novo Pharmaceutical Research (688621.SH): ABA001 injection clinical trial application has been accepted.

Beijing Sun-Novo Pharmaceutical Research (688621.SH) announced that recently, the company and its wholly-owned subsidiary Beijing Arna Technology Co., Ltd. received the "Acceptance Notice" issued by the National Medical Products Administration for the clinical trial application of the research project ABA001 injection. The ABA001 injection is intended to be applied for the treatment of hypertension. The ABA001 injection is a small interfering nucleotide drug targeting the messenger RNA (mRNA) gene of angiotensinogen (AGT), coupled with the N-acetylgalactosamine (GalNAc) delivery system. It can accurately deliver the drug to liver cells, target and silence the mRNA of AGT through the interference mechanism of siRNA, inhibit the synthesis of AGT protein at the source, and fundamentally suppress the Renin-Angiotensin-Aldosterone System (RAAS) that raises blood pressure, thereby reducing blood pressure. Clinical studies of similar siRNA drugs like Zilebesiran have confirmed the effectiveness and safety of this mechanism, with a single dose providing sustained efficacy for up to 24 weeks, providing sufficient scientific basis for the development of the ABA001 injection. Non-clinical studies have shown that this product can significantly reduce blood pressure at a dose of 1mg/kg, with good animal tolerance and high safety, and is expected to achieve long-lasting blood pressure reduction with dosing every 3 months or every six months. Its long-acting dosing characteristics are expected to overcome existing treatment bottlenecks and provide a better treatment option for patients with hypertension.